Discover B7-H4 Recombinant Antibody for Advanced Research Applications

Alpha Lifetech Incorporation proudly presents its cutting-edge b7-h4 recombinant antibody, engineered for precision and efficacy in immunological research. B7-H4, also known as VTCN1, plays a critical role in regulating immune responses, making it a key target for cancer immunotherapy and other therapeutic applications, This recombinant antibody is meticulously developed to exhibit high affinity and specificity to B7-H4, ensuring reliable results in various assays, including flow cytometry, ELISA, and Western blotting. It is suitable for both in vitro and in vivo research, facilitating the exploration of B7-H4's role in immuno-oncology and beyond, Researchers can count on the consistent quality and performance of Alpha Lifetech's offerings, backed by extensive validation and support. Enhance your research with our B7-H4 recombinant antibody and contribute to the advancement of novel therapeutic strategies in the fight against cancer and other immune-related diseases. Discover the power of precision with Alpha Lifetech

Hot Selling Product

ADT1332-J695 Biosimilar-Recombinant Human Monoclonal Antibody

ALP64562-Recombinant Rhesus Macaque CD160 Protein, Fc Tag

ALP64507-Recombinant Rhesus Macaque CD47/MER6 Protein, His Tag, Flag Tag

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

ALP64512-Recombinant Human CD96 Protein, Fc Tag

ALP64515-Recombinant Human CD73 Protein, Fc Tag

The Secret to b7-h4 recombinant antibody Manufacturer More Than a Supplier - A Partner

At Alpha Lifetech Inc., we understand that being a supplier is not just about providing high-quality products; it's about being a reliable partner in your research and development journey. With a foundational team of scientists who have deep expertise in membrane Protein production, nanobody discovery, and monoclonal development, we have positioned ourselves distinctively in the biotechnology landscape. Our commitment to innovation has led to the successful launch of nearly 10,000 specialized reagents, cytokines, and drug target antibodies, designed to meet the diverse needs of the global scientific community. What sets Alpha Lifetech apart is our dedication to collaboration. We don’t just supply products; we offer tailored solutions and personalized support to help you navigate the complexities of your projects. By engaging with us, you gain access to not only our vast product portfolio but also our wealth of knowledge and expertise. We strive to understand your specific requirements and challenges, ensuring that we provide the right tools and insights to advance your research goals effectively. Choosing Alpha Lifetech Inc. means entering a partnership where quality, reliability, and innovation converge. Our goal is to empower researchers and scientists by delivering exceptional products and support, ultimately fueling breakthroughs that drive science forward. Together, we can make a significant impact in the field of life sciences.

The Secret to b7-h4 Recombinant Antibody Manufacturer More Than a Supplier - A Partner

Dimension	Details
Manufacturing Capacity	100,000 units/month
Quality Control Certification	ISO 9001, ISO 13485
Lead Time	4-6 weeks
Customization Options	Tailored affinity, conjugation types
Technical Support	Available for applications and optimization
Distribution Network	Global, with local partners
Customer Feedback	95% satisfaction rate
Research Collaboration	Ongoing projects with universities

Trends in Recombinant Antibody Production and Market Growth

The chart above illustrates the upward trend in the production of recombinant antibodies from 2019 to 2023. Starting with a production volume of 50,000 units in 2019, the output steadily increased each year, reflecting a growing demand for these essential biopharmaceuticals. By 2023, production is projected to reach 170,000 units, signaling a robust expansion in the market. This growth can be attributed to advancements in biotechnological processes, increased investment in research and development, and a higher prevalence of diseases that require targeted therapies. As the landscape for therapeutic antibodies continues to evolve, manufacturers are positioning themselves not just as suppliers but as partners in innovation and development, fostering close collaborations with research institutions and healthcare providers to meet the dynamic needs of the industry.